A new biomarker shows potential to evaluate treatment response for metastatic colorectal cancer
A study led by researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d’Oncologia (ICO) analysed peripheral blood samples from patients with metastatic colorectal cancer and identified a potential biomarker indicating the effectiveness of oxaliplatin-based treatment. The research has been published in the journal Biomedicine & Pharmacotherapy.